GlassScriptPhysician profile
Inder Sunilkumar Patel
NPI 1013256700
$1,901.38
in general payments reported to CMS, 2019-2025
25 companies · $774 in 2025
The $774 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.75 · 2023: $333 · 2024: $721 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.80 |
| Education | $130.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $289.00 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $194.85 | 2024-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $187.29 | 2023-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $119.15 | 2025 | Vafseo |
| Amgen INC. | $117.45 | 2024-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $117.23 | 2023-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $116.33 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $113.46 | 2024 | |
| Fresenius USA Marketing, INC. | $102.87 | 2022-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $79.35 | 2023-2025 | Jynarque |
| Travere Therapeutics, INC. | $72.94 | 2025 | |
| Horizon Therapeutics Plc | $54.27 | 2023 | Krystexxa |
| Ardelyx, INC. | $46.43 | 2023-2024 | Ibsrela |
| Lilly USA, LLC | $33.82 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.03 | 2024 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.89 | 2022-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $27.00 | 2023 | |
| Leadiant Biosciences, INC. | $24.08 | 2024 | Carnitor |
| Aurinia Pharma U.S., INC. | $23.90 | 2023 | Lupkynis |
| Vifor Pharma, INC. | $23.60 | 2023 | Veltassa |
| Scpharmaceuticals INC. | $22.89 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.32 | 2024 | Xifaxan, Trulance |
| Genzyme Corporation | $22.00 | 2024 | |
| Cormedix INC. | $17.86 | 2025 | Defencath |
| Kyowa Kirin, INC. | $17.37 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inder Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.